Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInfectious Disease Physician in Hillsborough, NJ
NPI: 1023084928Primary Practice Location
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL - SOMERSET
110 Rehill Ave, Somerville, NJ
Primary Employer
ID Care LLC
idcare.com
HQ Phone
Get M.D. Ronald's Phone Numberphone_androidMobile
Get M.D. Ronald's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNJ State Medical License
FL State Medical License
2020
NJ State Medical License
1983 - 2025
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Infectious Disease
Harvard School of Public Health
MHCM • Healthcare Leadership
2010 - 2012
Rutgers Health/Robert Wood Johnson Medical School
Residency • Internal Medicine
1982 - 1986
Rutgers Robert Wood Johnson Medical School
Medical School
Until 1982
Rensselaer Polytechnic Institute
B.S. • Cum Laude
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 103 | 173 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 99 | 207 |
| 3 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 49 | 154 |
| 4 | 36410Insertion of needle into vein, patient 3 years or older | 31 | 85 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs.
Authors: Kay Schwebke, Steven Schmitt, Russell Petrak
Publication Date: 2013-09-28
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.
Authors: Brunetti, Luigi, Diawara, Oumou, Tsai, Andrew, Firestein, Bonnie L, Nahass, Ronald G, Poiani, George, Schlesinger, Naomi
Journal: J Clin Med
Publication Date: 2020-09-14
Lead Sponsor: Arbutus Biopharma Corporation
Intervention / Treatment: DRUG: AB-729, DRUG: Peg-IFNα-2a
Lead Sponsor: ViiV Healthcare
Collaborators: Janssen, LP
Intervention / Treatment: DRUG: Cabotegravir Tablets, DRUG: Rilpivirine Tablets, DRUG: Cabotegravir Injectable Suspension (CAB LA), DRUG: Rilpivirine Injectable Suspension (RPV LA), DRUG: BIKTARVY Tablets (BIK)
Lead Sponsor: ViiV Healthcare
Collaborators: GlaxoSmithKline, PPD Development, LP
Intervention / Treatment: DRUG: DTG/3TC FDC, DRUG: CAR
